NCT01895361 2020-01-31SUSTAINReprixys Pharmaceutical CorporationPhase 2 Completed198 enrolled 18 charts 1 FDA
NCT00236041 2014-05-09Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)Teva Branded Pharmaceutical Products R&D, Inc.Phase 2 Completed38 enrolled
NCT00236093 2014-05-09Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough PainTeva Branded Pharmaceutical Products R&D, Inc.Phase 2 Completed